

MOLINA HEALTHCARE Service Authorization (SA) Form ANTIMIGRAINE AGENTS, OTHERS

If the following information is not complete, correct, and legible, the SA process could be delayed. Please use one form per member.

MEMBER INFORMATION													
Last Name:	First Name:												
Medicaid ID Number:	Date of Birth:												
Gender: Male Female	Weight in Kilograms:												
PRESCRIBER INFORMATION													
Last Name:	First Name:												
NPI Number:													
Phone Number:	Fax Number:												
DRUG INFORMATION													
Drug Name/Form:													
Strength:													
Dosing Frequency:													
Length of Therapy:													
Quantity per Day:													
Preventive tre	atment of migraine												
Preferred Agents *step edit required	Non-Preferred Agents (SA required)												
Aimovig®, Ajovy® and Ajovy® autoinjector	Emgality® syringe (100 mg)												
Emgality® pen and syringe (120 mg), Nurtec® ODT	Qulipta™												
	ment of migraine												
Preferred Agents (No SA with trial of 2 generic	Non-Preferred Agents (SA required)												
triptans)	, , ,												
Nurtec® ODT, Ubrelvy™	Reyvow®, Trudhesa™												

MolinaHealthcare.com

MCC Virginia SA Form: Antimigraine Agents, Others

Member's Last Name:										Member's First Name:														
DR	DRUG INFORMATION (Continued)																							
Ple	Please identify why the preferred agents cannot be used:																							
DI	DIAGNOSIS AND MEDICAL INFORMATION																							
All	All drugs in this class are eligible to receive a SIX (6)-month approval. Complete the following																							
qu	questions. For Preventive treatment of migraine, does the member meet the *step edit AND the																							
fol	lowir	ng cı	riteria	a?																				
1.	 Does the member have a diagnosis of migraine with or without aura based on International Classification of Headache Disorders (ICHD-III) diagnostic criteria? AND 																							
2		Yes] No > 10		of		. A.	ın															
۷. ۱			nber ──	_	yea	IS OI	age	? Ar	שא															
_		Yes	L	No													0.4							
3.		the Yes	mem 	ber f] No	nad ≥	≥ 4 m	iigrai	ne d	ays	per r	nont	h fo	or at	leas	t 3 m	onth	s? A	ND						
4.	*Ha	s the	men	nber	tried	and	faile	d a	≥ 1 r	nont	h tria	l of	f any	2 of	the	follov	ving	oral	gene	ric m	edic	ation	s?	
			lepre			-																		
			block epiler			-	-			-		mc	olol, a	atend	olol)									
			otens				-		-		•	iote	ensir	ı II re	ecept	or bl	ocke	rs (e	.g., li	sinor	oril, c	ande	sarta	an)
		Yes	\square N	lo																				
Fo	r ren	ewa	l, cor	nple	te th	e fo	llow	ing d	ques	stion	to r	ece	eive	a TV	VEL\	/E (1	2)- m	onth	n app	orova	al.			
1.	Did	the r	nemb	er d	emo	nstra	ıte si	gnifi	cant	deci	rease	e in	the	num	ber,	frequ	iency	, or	inten	sity (of he	adac	hes?	
		Yes		No												·				-				
				-																				
Me	mbe	r's L	ast N	lam	e:								Member's First Name:											
	r Ac teria		treat	mei	nt of	mig	grair	ne, c	does	s the	e me	ml	ber	mee	t the	*st	ер е	dit /	AND	the	follo	win	g	
1. Does the member have a diagnosis of migraine with or without aura? AND																								
	`	Yes] No																				
2.	Is th	e me	embe	r ≥ 1	8 ye	ars c	of ag	e? A	ND															
		Yes] No																				

Page 2 of 3

(Form continued on next page.)

MCC Virginia SA Form: Antimigraine Agents, Others

3.	*Has	the	mem	ber trie	ed an	d faile	d (o	r has	con	train	dic	atior	s to)	two	prefe	erred	tript	an m	nedic	ation	ıs?		
	Y	es		No																			
4.	Prior to initiation of Trudhesa™, a cardiovascular evaluation is recommended. Has this been completed?																						
	ПΥ	es		No																			
Fo	r rene	wal,	con	nplete	the fo	ollow	ing (ques	stion	to r	ece	eive	a TW	/ELV	/E (1	2)-m	onth	app	rova	al.			
2.	Did th	ne m	emb	er dem	nonstr	ate si	anifi	cant	deci	rease	e in	the	numl	ber, f	frequ	ency	, or i	inten	sity (of hea	adacl	nes?	
	☐ Yes ☐ No																						
Member's Last Name: Member's First Name:																							
Fo	For Episodic Cluster Headache, does the member meet the following criteria?																						
1.	. Does the member have a diagnosis of episodic cluster headache? AND																						
	Y	es		No																			
2.	Is the member ≥ 18 years of age? AND																						
	Y	es		No																			
3.	Has the member experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain- free periods lasting at least three months? AND																						
	Δ	es		No																			
4.	. Medication will not be used in combination with another CGRP antagonist or inhibitor used for the preventive treatment of migraines? AND																						
	Yes No																						
5.	Has the member tried and failed (or has contraindications to) at least one standard prophylactic (preventive) pharmacologic therapy for cluster headache?																						
	Y	es		No																			
Fo	r rene	wal,	con	nplete	the fo	ollow	ing (ques	stion	to r	ece	eive	a TW	/ELV	/E (1	2)-m	onth	арр	rova	al.			
1.	Did th	he m	emb	er dem	nonstr	ate si	gnifi	cant	deci	rease	e in	the	numl	ber, f	frequ	ency	, or i	inten	sity (of hea	adac	hes?	
	Y	es		No																			
Prescriber Signature (Required)																	Da	ite					

By signature, the Physician confirms the above information is accurate and verifiable by member records.

Please include ALL requested information; incomplete forms will delay the SA process. Submission of documentation does NOT guarantee coverage by Molina Complete Care.

The completed form may be faxed to (844) 278-5731, or you may call (800) 424-4518 (TTY/TDD:711)